Caspofungin: an advanced treatment approach for suspected or confirmed invasive aspergillosis

International Journal of Antimicrobial Agents

Volumn 27, Issue 6, 2006, Pages 457-467

  Maertens, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Antifungal therapy; Aspergillosis; Caspofungin; Echinocandin; Mycoses

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BARBITURIC ACID DERIVATIVE; CARDIOVASCULAR AGENT; CASPOFUNGIN; CYCLOSPORIN A; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; NUCLEOSIDE DERIVATIVE; OPIATE; ORAL CONTRACEPTIVE AGENT; POLYENE ANTIBIOTIC AGENT; PSYCHOTROPIC AGENT; PYRROLE DERIVATIVE; RAPAMYCIN; STEROID; TACROLIMUS; UNINDEXED DRUG; VINCRISTINE; VORICONAZOLE;

ANTIGEN DETECTION; ASPERGILLOSIS; BONE MARROW DEPRESSION; BRAIN ABSCESS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; DRUG UPTAKE; ENZYME INHIBITION; ESOPHAGUS CANDIDIASIS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUSHING; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOLOGY; HUMAN; HYPERCALCEMIA; IMMUNE DEFICIENCY; LIVER TOXICITY; LUNG ASPERGILLOSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SHORT SURVEY; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HUMANS; PEPTIDES, CYCLIC;

EID: 33646792916     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.03.019     Document Type: Short Survey

References (87)

1. Singh N., and Paterson D.L. Aspergillus infections in transplant recipients. Clin Microbiol Rev 18 (2005) 44-69
2. Denning D.W., and Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 12 (1990) 1147-1201
3. Patterson T.F., Kirkpatrick W.R., White M., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79 (2000) 250-260
4. Morgan J., Wannemuehler K.A., Marr K.A., et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 43 Suppl. 1 (2005) S49-S58
5. Maertens J., and Boogaerts M. Caspofungin in the treatment of candidosis and aspergillosis. Int J Infect Dis 7 (2003) 94-101
6. Rankin N.E. Disseminated aspergillosis and moniliasis associated with agranulocytosis and antibiotic therapy. Br Med J 1 (1953) 918-919
7. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33 (2001) 1692-1696
8. Groll A.H., Shah P.M., Mentzel C., Schneider M., Just-Nuebling G., and Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33 (1996) 23-32
9. Chandrasekar P.H., Alangaden G., and Manavathu E. Aspergillus: an increasing problem in tertiary care hospitals?. Clin Infect Dis 30 (2000) 984-985
10. Marr K.A., Carter R.A., Crippa F., Wald A., and Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34 (2002) 909-917
11. Wiederhold N.P., Lewis R.E., and Kontoyiannis D.P. Invasive aspergillosis in patients with hematologic malignancies. Pharmacotherapy 23 (2003) 1592-1610
12. Denning D.W., Follansbee S.E., Scolaro M., Norris S., Edelstein H., and Stevens D.A. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 324 (1991) 654-662
13. Rosenzweig S.D., and Holland S.M. Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol 113 (2004) 620-626
14. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 (2002) 7-14
15. Maertens J., Theunissen K., Verbeken E., et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 126 (2004) 852-860
16. Maertens J., Verhaegen J., Lagrou K., Van Eldere J., and Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97 (2001) 1604-1610
17. Caillot D., Casasnovas O., Bernard A., et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15 (1997) 139-147
18. Hebart H., Loffler J., Meisner C., et al. Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 181 (2000) 1713-1719
19. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., et al. Multicenter clinical evaluation of the (1→3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41 (2005) 654-659
20. Leenders A.C., Daenen S., Jansen R.L., et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103 (1998) 205-212
21. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340 (1999) 764-771
22. Prentice H.G., Hann I.M., Herbrecht R., et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98 (1997) 711-718
23. Walsh T.J., Hiemenz J.W., Seibel N.L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26 (1998) 1383-1396
24. Sundar S. Liposomal amphotericin B. Lancet 357 (2001) 801-802
25. Maertens J., Theunissen K., and Boogaerts M. Invasive aspergillosis: focus on new approaches and new therapeutic agents. Curr Med Chem Anti-Infective Agents 1 (2002) 65-81
26. Frothingham R. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. Clin Infect Dis 35 (2002) 896-897
27. Wingard J.R. Lipid formulations of amphotericins: are you a lumper or a splitter?. Clin Infect Dis 35 (2002) 891-895
28. Bowden R., Chandrasekar P., White M.H., et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35 (2002) 359-366
29. Walsh T.J., Goodman J.L., Pappas P., et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45 (2001) 3487-3496
30. Paterson D.L., and Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 78 (19991) 123-138
31. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 (2001) 358-366
32. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
33. Vermes A., Guchelaar H.J., and Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46 (2000) 171-179
34. Denning D.W., Ribaud P., Milpied N., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34 (2002) 563-571
35. Walsh T.J., Lutsar I., Driscoll T., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 21 (2002) 240-248
36. Boucher H.W., Groll A.H., Chiou C.C., and Walsh T.J. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64 (2004) 1997-2020
37. IV/oral VFEND (voriconazole). Full prescribing information. New York, NY: Pfizer Inc. http://www.vfend.com/prescribe.asp [accessed 8 August 2005].
38. Sporinox (itraconazole). Full U.S. prescribing information. Titusville, NJ: Janssen Pharmaceutica Products, L.P. www.sporanox.com/active/janus/en_US/assets/common/company/pi/sporanox.pdf [accessed 5 April 2006].
39. Groll A.H. Itraconazole-perspectives for the management of invasive aspergillosis. Mycoses 45 Suppl. 3 (2002) 48-55
40. Purkins L., Wood N., Greenhalgh K., Allen M.J., and Oliver S.D. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 56 Suppl. 1 (2003) 10-16
41. Bates D.W., and Yu D.T. Clinical impact of drug-drug interactions with systemic azole antifungals. Drugs Today (Barc) 39 (2003) 801-813
42. Rybowicz J., and Gurk-Turner C. Caspofungin: the first agent available in the echinocandin class of antifungals. Proc (Bayl Univ Med Cent) 15 (2002) 97-99
43. Kurtz M.B. New antifungal drug targets: a vision for the future. ASM News 64 (1999) 31-39
44. Diekema D.J., Messer S.A., Hollis R.J., Jones R.N., and Pfaller M.A. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41 (2003) 3623-3626
45. Onishi J., Meinz M., Thompson J., et al. Discovery of novel antifungal (1,3)-beta-d-glucan synthase inhibitors. Antimicrob Agents Chemother 44 (2000) 368-377
46. Barchiesi F., Schimizzi A.M., and Fothergill A.W. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 18 (1999) 302-304
47. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 36 (1998) 2950-2956
48. Bartizal K., Gill C.J., Abruzzo G.K., et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 41 (1997) 2326-2332
49. Krishnarao T.V., and Galgiani J.N. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 41 (1997) 1957-1960
50. Vazquez J.A., Lynch M., Boikov D., and Sobel J.D. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 41 (1997) 1612-1614
51. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
52. Abruzzo G.K., Flattery A.M., Gill C.J., et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 41 (1997) 2333-2338
53. Abruzzo G.K., Gill C.J., Flattery A.M., et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 44 (2000) 2310-2318
54. Gonzalez G.M., Tijerina R., Najvar L.K., et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 45 (2001) 1854-1859
55. Powles M.A., Liberator P., Anderson J., et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 42 (1998) 1985-1989
56. Maertens J., Raad I., Petrikkos G., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
57. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
58. Trenschel R., Ditschkowski M., Elmaagacli A.H., et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant 35 (2005) 583-586
59. Candoni A., Mestroni R., Damiani D., et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 75 (2005) 227-233
60. Sanz-Rodriguez C, Martino R, Canales M, et al. Caspofungin therapy in documented fungal infections in patients with hematological disorders: Spanish experience before licensure of the drug (abstract). In: Proceedings of the Annual Meeting of the American Society of Haematology; 2001 December 7-11; Philadelphia, PA.
61. Glasmacher A, Cornley O, Orlopp K, et al. Efficacy of caspofungin in neutropenic and non-neutropenic patients (abstract). In: Proceedings of the 29th Annual Meeting of the European Group for Blood and Marrow Transplantation; 2003 March 23-26; Istanbul, Turkey.
62. Morrissey CO, Slavin MA, O'Reilly MA, Daffy J, Coyle L. Caspofungin (CAS) as salvage therapy (Rx) for invasive aspergillosis (IA): results of the Australian Compassionate Access Program (CAP) (abstract). In: Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 October 30-November 2; Washington DC.
63. Kartsonis N.A., Saah A.J., Joy L.C., Taylor A.F., and Sable C.A. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 50 (2005) 196-205
64. Aliff T.B., Maslak P.G., Jurcic J.G., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97 (2003) 1025-1032
65. Kontoyiannis D.P., Hachem R., Lewis R.E., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98 (2003) 292-299
66. Marr K.A., Boeckh M., Carter R.A., Kim H.W., and Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39 (2004) 797-802
67. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin combined with other antifungals in adults with invasive aspergillosis refractory or intolerant to prior therapy: final data. In: Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 December 16-19; Washington DC (Abstract M-954).
68. Koss T., Bagheri B., Zeana C., Romagnoli M.F., and Grossman M.E. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J Am Acad Dermatol 46 (2002) 945-947
69. Taccone F.S., Marechal R., Meuleman N., and Aoun M. Caspofungin salvage therapy in a neutropenic patient with probable invasive aspergillosis: a case report. Support Care Cancer 11 (2003) 742-744
70. Cooke F.J., Terpos E., Boyle J., Rahemtulla A., and Rogers T.R. Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin. Clin Microbiol Infect 9 (2003) 1238-1241
71. Colombo A.L., and Rosas R.C. Successful treatment of an Aspergillus brain abscess with caspofungin: case report of a diabetic patient intolerant of amphotericin B. Eur J Clin Microbiol Infect Dis 22 (2003) 575-576
72. Sallmann S., Heilmann A., Heinke F., et al. Caspofungin therapy for Aspergillus lung infection in a boy with chronic granulomatous disease. Pediatr Infect Dis J 22 (2003) 199-200
73. Anttila V.J., Piilonen A., and Valtonen M. Co-administration of caspofungin and cyclosporine to a kidney transplant patient with pulmonary Aspergillus infection. Scand J Infect Dis 35 (2003) 893-894
74. Groetzner J., Kaczmarek I., Landwehr P., et al. Caspofungin (CSF) for invasive aspergillosis after thoracic organ transplantation: first clinical experience of 11 patients. Transplantation 78 Suppl. 1 (2004) 493
75. Carby M.R., Hodson M.E., and Banner N.R. Refractory pulmonary aspergillosis treated with caspofungin after heart-lung transplantation. Transpl Int 17 (2004) 545-548
76. Ifran A., Kaptan K., and Beyan C. Efficacy of caspofungin in prophylaxis and treatment of an adult leukemic patient with invasive pulmonary aspergillosis in allogeneic stem cell transplantation. Mycoses 48 (2005) 146-148
77. Denning D.W., Marinus A., Cohen J., et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 37 (1998) 173-180
78. Marr K.A., Boeckh M., and Kim H.W. Reply to Cesaro and Visintin. Clin Infect Dis 40 (2005) 1075-1076
79. Coleman J.M., Hogg G.G., Rosenfeld J.V., and Waters K.D. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery-case report and review of the literature. Neurosurgery 36 (1995) 858-863
80. Shuper A., Levitsky H.I., and Cornblath D.R. Early invasive CNS aspergillosis. An easily missed diagnosis. Neuroradiology 33 (1991) 183-185
81. Schwartz S., Milatovic D., and Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 97 (1997) 663-665
82. Villanueva A., Gotuzzo E., Arathoon E.G., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113 (2002) 294-299
83. Arathoon E.G., Gotuzzo E., Noriega L.M., Berman R.S., DiNubile M.J., and Sable C.A. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46 (2002) 451-457
84. Villanueva A., Arathoon E.G., Gotuzzo E., Berman R.S., DiNubile M.J., and Sable C.A. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33 (2001) 1529-1535
85. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
86. Marr K.A., Hachem R., Papanicolaou G., et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 6 (2004) 110-116
87. Sanz-Rodriguez C., Lopez-Duarte M., Jurado M., et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 34 (2004) 13-20